NCT06251232View on ClinicalTrials.gov

Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
HepatotoxicityIdiosyncratic Drug EffectPrednisone
Interventions
DRUG

Prednisone

Placebo

All Listed Sponsors
lead

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

OTHER

NCT06251232 - Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity | Biotech Hunter | Biotech Hunter